RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology

In brief

Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy

Key facts

Study ID
NCT03118986
Run by
The Hospital for Sick Children
People needed
200
Starts
2017-08-10
Expected to finish
2026-04-01
Last updated by the study team
2025-10-08

Who can join

Age: 3 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.